Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma

For patients with relapsed or refractory multiple myeloma (RRMM), the addition of the oral drug mezigdomide to standard treatment with carfilzomib and dexamethasone markedly improved progression-free survival over standard treatment alone, according to results from a phase 3 clinical trial led by investigators at Dana-Farber Cancer Institute.

By
May 29, 2026
5 min

Dana-Farber

1

Mezigdomide significantly improves progression-free survival in relapsed refractory multiple myeloma compared to standard treatment alone.
2

In the SUCCESSOR-2 trial, patients receiving mezigdomide had a median progression-free survival of 18 months versus 8.3 months for standard treatment.
3

The majority of patients on mezigdomide (80.2%) responded to treatment, with 26.7% achieving complete response, compared to 53.4% and 8.9% in the standard group.
4

Mezigdomide has a manageable safety profile, with higher treatment-related side effects (83.7%) than standard treatment (56.5%), but no unexpected adverse effects.
5

Ongoing studies aim to confirm mezigdomide's effectiveness in combination with other therapies and explore its potential in enhancing immune activity.

Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma

1

2

3

4

5

Original Source(s)

Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma

Related Content

Error in Number of Cancers

A precision T-cell therapy stalls treatment-resistant cancers in clinical trial

Post–Acute Care Facility Utilization and Outcomes Among Medicare Beneficiaries Undergoing Inpatient Cancer